RSS Feeds
Search

Companies

Companies

Displaying 11..18 of 18 - per page Previous page
Order by
Fluofarma
High Content Screening Services More
Alizyme
A biopharmaceutical development company specialising in gastro-intestinal diseases, and obesity and related disorders eg diabetes More
Direct Haler
Direct-Haler A/S is a privately owned drug delivery device company focusing on research & development and out-licensing of world-wide patented device technologies for pulmonary and nasal delivery More
Metcon Medicin
Metcon Medicin AB is a privately held pharmaceutical R&D company focusing on the development of pharmaceuticals within the fields of diabetes and metabolic diseases. More
DeveloGen
A drug discovery company developing novel therapies for metabolic disorders, such as obesity and diabetes. More
Lacer
LACER, S.A. is a Spanish company specialized in human health care on a worldwide scale. LACER researches and develops technologically advanced products & services of an innovative nature. More
Bayer HealthCare AG
Pharmaceuticals, Biological Products, Consumer Care, Diagnostics, Animal Health, Diabetes Care More
MedicAlarm
More
Displaying 11..18 of 18 - per page Previous page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Diabetes Drug Discoveries 2009: what the future holds
Feb 2009 - 160 pages - $1,390
Epidemiology: Diabetes in India - a country faced with a mammoth diabetes epidemic
Mar 2011 - 43 pages - $5,700
Epidemiology: Diabetes in Australia - Despite government efforts to promote healthy lifestyles, the number of cases of diabetes in Australia is set to soar
Jun 2011 - 44 pages - $5,700
Epidemiology: Type 1 diabetes - There will be an increasing number of new cases of type 1 diabetes in the seven major markets in the coming decade
Dec 2010 - 25 pages - $5,700
Epidemiology: Diabetes in China - Aging population, rising overweight and obesity are driving the diabetes epidemic
Mar 2011 - 42 pages - $5,700
Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes
Jul 2011 - 92 pages - $7,600
Hot Topics in Type 2 Diabetes: Complications and Comorbidities – Physician insight on diabetic complications, comorbidities and treatment
Aug 2011 - 55 pages - $5,700
Epidemiology: Type 2 Diabetes
Dec 2010 - 31 pages - $5,700
Tradjenta (linagliptin) - First Member of DPP - 4 Inhibitor Class to Be Approved by US FDA at One Dosage Strength
May 2011 - 7 pages - $500
Byetta Wave 4 Tracking Survey; Trends in Usage of Type II Diabetes Mellitus Therapeutics
Nov 2007 - $2,500
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us